During	IN	O
the	DT	B
race	NN	O
to	TO	B
develop	VB	O
an	DT	O
oral	JJ	O
polio	NN	O
vaccine	NN	O
several	JJ	B
large	JJ	O
scale	NN	O
human	JJ	O
trials	NNS	O
were	VBD	B
undertaken	VBN	O
.	.	O

In	IN	O
Africa	NNP	O
,	,	B
the	DT	I
vaccines	NNS	O
were	VBD	B
administered	VBN	O
to	IN	B
roughly	RB	O
one	CD	B
million	CD	O
people	NNS	B
in	IN	O
the	DT	B
Belgian	JJ	O
territories	NNS	O
,	,	B
now	RB	O
the	DT	B
Democratic	NNP	O
Republic	NNP	O
of	IN	B
the	DT	I
Congo	NNP	O
,	,	B
Rwanda	NNP	O
and	CC	B
Burundi	NNP	O
.	.	O

However	RB	O
,	,	B
recent	JJ	O
opposition	NN	O
to	IN	B
vaccination	NN	O
campaigns	NNS	O
has	VBZ	B
evolved	VBN	O
,	,	B
often	RB	I
relating	VBG	O
to	IN	B
fears	NNS	O
that	IN	O
the	DT	B
vaccine	NN	O
might	MD	B
induce	VB	O
sterility	NN	O
.	.	O

The	DT	B
disease	NN	O
has	VBZ	B
since	IN	O
resurged	VBN	O
in	IN	O
Nigeria	NNP	O
and	CC	B
in	IN	O
several	JJ	B
other	JJ	I
African	JJ	O
nations	NNS	O
,	,	B
which	WDT	I
epidemiologists	VBZ	O
cite	VBP	O
is	VBZ	B
due	JJ	O
to	IN	B
refusals	NNS	O
by	IN	O
certain	JJ	B
local	JJ	O
populations	NNS	O
to	TO	B
allow	VB	O
their	PRP$	O
children	NNS	O
to	TO	B
receive	VB	O
the	DT	B
polio	NN	O
vaccine	NN	O
.	.	O

